Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Screen on your Watchlists and Portfolios with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Abbott Laboratories (ABT)

Abbott Laboratories (ABT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 220,593,296
  • Shares Outstanding, K 1,738,872
  • Annual Sales, $ 41,950 M
  • Annual Income, $ 13,402 M
  • EBIT $ 9,438 M
  • EBITDA $ 12,656 M
  • 60-Month Beta 0.72
  • Price/Sales 5.33
  • Price/Cash Flow 19.51
  • Price/Book 4.36

Options Overview Details

View History
  • Implied Volatility 21.41% (+1.18%)
  • Historical Volatility 20.86%
  • IV Percentile 46%
  • IV Rank 18.98%
  • IV High 42.50% on 04/07/25
  • IV Low 16.47% on 01/24/25
  • Expected Move (DTE 2) 1.56 (1.23%)
  • Put/Call Vol Ratio 0.41
  • Today's Volume 3,733
  • Volume Avg (30-Day) 8,583
  • Put/Call OI Ratio 0.80
  • Today's Open Interest 205,219
  • Open Int (30-Day) 197,486
  • Expected Range 125.15 to 128.27

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 27 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate 1.50
  • Number of Estimates 9
  • High Estimate 1.51
  • Low Estimate 1.49
  • Prior Year 1.34
  • Growth Rate Est. (year over year) +11.94%

Price Performance

See More
Period Period Low Period High Performance
1-Month
120.70 +4.98%
on 12/10/25
132.02 -4.03%
on 11/18/25
-3.32 (-2.55%)
since 11/17/25
3-Month
120.70 +4.98%
on 12/10/25
137.49 -7.84%
on 09/22/25
-7.46 (-5.56%)
since 09/17/25
52-Week
110.86 +14.30%
on 01/15/25
141.23 -10.28%
on 03/04/25
+13.42 (+11.85%)
since 12/17/24

Most Recent Stories

More News
1 Safe-and-Steady Stock to Consider Right Now and 2 We Turn Down

1 Safe-and-Steady Stock to Consider Right Now and 2 We Turn Down

ABT : 126.71 (-0.12%)
EPC : 18.15 (+2.20%)
FAF : 63.70 (-0.31%)
Abbott increases quarterly dividend for 54th consecutive year

ABBOTT PARK, Ill. , Dec. 12, 2025 /PRNewswire/ -- Abbott (NYSE: ABT) today announced that its board of directors has increased the company's quarterly common dividend to 63 cents per share, an increase...

ABT : 126.71 (-0.12%)
AI Turns Health and Wellness Data into Gold as $110B Market Explodes by 2030

Issued on behalf of Aleen Inc. VANCOUVER – Baystreet.ca News Commentary – Artificial intelligence is turning fragmented health data into actionable insights, fundamentally reshaping how patients,...

ABT : 126.71 (-0.12%)
WELL.TO : 3.90 (-2.26%)
MDT : 98.30 (+0.59%)
WHTCF : 2.8440 (-1.66%)
RDNT : 71.24 (+0.02%)
ALEN-U.CN : 1.4500 (+8.21%)
Abbott's Lingo™ Now on Android™, Expanding Access to Real-Time Glucose Data

ABBOTT PARK, Ill. , Dec. 8, 2025 /PRNewswire/ -- Abbott (NYSE: ABT) today announced that Lingo , an over-the-counter continuous glucose monitor (CGM) and app, is now available for Android devices....

ABT : 126.71 (-0.12%)
2 Mega-Cap Stocks with Promising Prospects and 1 Facing Challenges

2 Mega-Cap Stocks with Promising Prospects and 1 Facing Challenges

ABT : 126.71 (-0.12%)
MA : 565.47 (-0.10%)
PEP : 150.08 (-0.19%)
University of Wisconsin Wins Abbott and Big Ten's 'We Give Blood' Competition as Campaign Donations Surge 319%, Helping Save Nearly 250,000 Lives

ABBOTT PARK, Ill. and INDIANAPOLIS , Dec. 6, 2025 /PRNewswire/ -- Amid the nation's worst blood shortage in a generation, the University of Wisconsin rallied Big Ten students, fans and alumni to...

ABT : 126.71 (-0.12%)
Muscles, the New Flex: Abbott Launches Two New Ensure® Max Protein Shakes to Tap into Growing Muscle Health Movement

ABBOTT PARK, Ill. , Dec. 4, 2025 /PRNewswire/ -- With America's growing focus on wellness and the quality of your years, muscle is emerging as a new metric for aging. That's why Abbott (NYSE: ABT),...

ABT : 126.71 (-0.12%)
How Is Medtronic's Stock Performance Compared to Other Medical Devices Stocks?

Medtronic has outperformed the Medical Devices industry over the past year, and analysts are cautiously optimistic about the stock’s prospects.

ABT : 126.71 (-0.12%)
IHI : 62.29 (+0.21%)
MDT : 98.30 (+0.59%)
Is Abbott Laboratories Stock Underperforming the S&P 500?

Abbott Laboratories has lagged behind the S&P 500 in recent months as well as over the past year, yet analysts remain strongly bullish on the stock’s prospects.

ABT : 126.71 (-0.12%)
$SPX : 6,721.43 (-1.16%)
BSX : 94.48 (+1.65%)
Exact Sciences Investor Alert By The Former Attorney General Of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Exact Sciences Corporation - EXAS

Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti , LLC (“KSF”) are investigating the proposed sale of Exact Sciences ...

ABT : 126.71 (-0.12%)
EXAS : 101.61 (-0.15%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Sell with a Strongest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Abbott Labs discovers, develops, manufactures & sells a diversified line of health care products. Established Pharmaceuticals Division includes branded generics business in the emerging markets. Medical Devices unit includes the diabetes care, vision care & vascular businesses. Diagnostics unit manufactures...

See More

Key Turning Points

3rd Resistance Point 129.34
2nd Resistance Point 128.50
1st Resistance Point 127.61
Last Price 126.71
1st Support Level 125.88
2nd Support Level 125.04
3rd Support Level 124.15

See More

52-Week High 141.23
Fibonacci 61.8% 129.63
Last Price 126.71
Fibonacci 50% 126.04
Fibonacci 38.2% 122.46
52-Week Low 110.86

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar